Vertex Pharmaceuticals Inc (VRTX) Com Stk
Sell:$479.53Buy:$479.87
$2.31
(0.48%)
0.09%- This stock can be held in a
Stocks and Shares ISA$2.31
(0.48%)$2.31
(0.48%)Company Information
About this company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Key people
Key facts
- EPICVRTX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92532F1003
- Market cap$119.76bn
- Employees6,100
- Shares in issue256.80m
- ExchangeNASDAQ
- IndexS&P 500, NASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.